Legal & General Group
ANIK icon

Legal & General Group’s Anika Therapeutics ANIK Stock Holding History

Legal & General Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7K Hold
1,081
– – ﹤0.01% 3050
2025
Q4 		$10.4K Hold
1,081
– – ﹤0.01% 3237
2025
Q3 		$10.2K Hold
1,081
– – ﹤0.01% 3281
2025
Q2 		$11.4K Sell
1,081
-2,101
-66% -$26.5K ﹤0.01% 3236
2025
Q1 		$47.8K Buy
3,182
+68
+2% +$1.13K ﹤0.01% 2731
2024
Q4 		$51.3K Hold
3,114
– – ﹤0.01% 2774
2024
Q3 		$76.9K Buy
3,114
+1,091
+54% +$28.3K ﹤0.01% 2747
2024
Q2 		$51.2K Sell
2,023
-719
-26% -$18.6K ﹤0.01% 2791
2024
Q1 		$69.6K Sell
2,742
-732
-21% -$17.7K ﹤0.01% 2757
2023
Q4 		$78.7K Sell
3,474
-8,566
-71% -$177K ﹤0.01% 2770
2023
Q3 		$224K Sell
12,040
-28,346
-70% -$588K ﹤0.01% 2700
2023
Q2 		$1.05M Buy
40,386
+4,158
+11% +$111K ﹤0.01% 2204
2023
Q1 		$1.04M Sell
36,228
-569
-2% -$16.9K ﹤0.01% 2138
2022
Q4 		$1.09M Buy
36,797
+1,208
+3% +$34.4K ﹤0.01% 2133
2022
Q3 		$847K Buy
35,589
+663
+2% +$15.3K ﹤0.01% 2198
2022
Q2 		$780K Buy
34,926
+61
+0.2% +$1.36K ﹤0.01% 2240
2022
Q1 		$875K Sell
34,865
-559
-2% -$17K ﹤0.01% 2264
2021
Q4 		$1.27M Buy
35,424
+1,313
+4% +$52.6K ﹤0.01% 2185
2021
Q3 		$1.45M Buy
34,111
+2,972
+10% +$122K ﹤0.01% 2151
2021
Q2 		$1.35M Sell
31,139
-9,591
-24% -$409K ﹤0.01% 2123
2021
Q1 		$1.67M Buy
40,730
+590
+1% +$22.4K ﹤0.01% 2051
2020
Q4 		$1.82M Buy
40,140
+148
+0.4% +$5.62K ﹤0.01% 1928
2020
Q3 		$1.42M Buy
39,992
+148
+0.4% +$5.35K ﹤0.01% 1916
2020
Q2 		$1.5M Buy
39,844
+2,796
+8% +$92.1K ﹤0.01% 1850
2020
Q1 		$1.07M Buy
37,048
+192
+0.5% +$7.77K ﹤0.01% 1831
2019
Q4 		$1.91M Buy
36,856
+3,068
+9% +$178K ﹤0.01% 1822
2019
Q3 		$1.85M Buy
33,788
+543
+2% +$27.9K ﹤0.01% 1759
2019
Q2 		$1.35M Sell
33,245
-470
-1% -$17.1K ﹤0.01% 1862
2019
Q1 		$1.02M Buy
33,715
+3,172
+10% +$109K ﹤0.01% 1968
2018
Q4 		$1.01M Sell
30,543
-800
-3% -$28.9K ﹤0.01% 1893
2018
Q3 		$1.32M Buy
31,343
+2,304
+8% +$91K ﹤0.01% 1870
2018
Q2 		$922K Buy
29,039
+1,762
+6% +$72.6K ﹤0.01% 1942
2018
Q1 		$1.35M Buy
27,277
+480
+2% +$27.1K ﹤0.01% 1783
2017
Q4 		$1.44M Sell
26,797
-342
-1% -$18.9K ﹤0.01% 1753
2017
Q3 		$1.57M Buy
27,139
+503
+2% +$26.3K ﹤0.01% 1686
2017
Q2 		$1.31M Buy
26,636
+2,560
+11% +$118K ﹤0.01% 1735
2017
Q1 		$1.04M Sell
24,076
-30
-0.1% -$1.43K ﹤0.01% 1777
2016
Q4 		$1.18M Buy
24,106
+11,910
+98% +$551K ﹤0.01% 1676
2016
Q3 		$581K Buy
12,196
+10,135
+492% +$501K ﹤0.01% 1625
2016
Q2 		$108K Hold
2,061
– – ﹤0.01% 2045
2016
Q1 		$92K Sell
2,061
-125
-6% -$5.07K ﹤0.01% 2105
2015
Q4 		$84K Hold
2,186
– – ﹤0.01% 2177
2015
Q3 		$69K Hold
2,186
– – ﹤0.01% 2260
2015
Q2 		$70K Hold
2,186
– – ﹤0.01% 2374
2015
Q1 		$90K Hold
2,186
– – ﹤0.01% 2106
2014
Q4 		$89K Hold
2,186
– – ﹤0.01% 2068
2014
Q3 		$81K Buy
+2,186
New +$94.5K ﹤0.01% 2042

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Legal & General Group's ANIK Position: Q1 2026 in Review

Legal & General Group held its Anika Therapeutics (ANIK) position steady in Q1 2026 at 1,081 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

Legal & General Group first reported a position in ANIK in Q3 2014 and has held it in 47 quarters since. The position peaked at $1.91M in Q4 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Legal & General Group held 1,081 shares of Anika Therapeutics worth $15.7K as of Q1 2026.
  • Legal & General Group left its Anika Therapeutics share count unchanged in Q1 2026.
  • Anika Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3050 holding.
  • Legal & General Group first reported a position in Anika Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Anika Therapeutics position peaked at $1.91M in Q4 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.